NASDAQ: $EYPT
A Potential Breakthrough for Wet AMD
EyePoint Pharmaceuticals has shared promising topline results from the LUGANO clinical trial, the first of two pivotal Phase 3 studies evaluating the efficacy and safety of Duravyu™ (EYP-1901). Designed as a potential treatment for wet age-related macular degeneration (wet AMD), this investigative therapy is being studied as a sustained-delivery intravitreal insert.
Key Findings from the LUGANO Trial
The LUGANO trial met its primary endpoint, demonstrating that Duravyu 2.7mg was non-inferior to the standard-of-care aflibercept in terms of best-corrected visual acuity (BCVA) change from baseline at 36 weeks. The results underscore the potential for a long-acting treatment option for patients managing chronic retinal diseases.
- Efficacy: Duravyu met the primary endpoint of non-inferiority to aflibercept.
- Dosing Advantage: The study highlights the potential for significantly reduced treatment burdens compared to current standard therapies.
- Safety Profile: The data indicated that Duravyu was generally well-tolerated, consistent with observations from earlier clinical studies.
Looking Ahead
With these positive results from the LUGANO trial, the medical community looks forward to the ongoing results from the VERONA Phase 3 trial. EyePoint Pharmaceuticals continues to focus on developing innovative, sustained-release treatments that aim to improve patient outcomes and quality of life in the field of ophthalmology.
Source: Read More